Systematic review with meta-analysis: association between acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs) and risk of Crohn's disease and ulcerative colitis exacerbation

被引:54
作者
Moninuola, O. O. [1 ]
Milligan, W. [2 ]
Lochhead, P. [3 ]
Khalili, H. [3 ,4 ,5 ]
机构
[1] Harvard Univ, TH Chan Sch Publ Hlth, Boston, MA 02115 USA
[2] Univ Aberdeen, Aberdeen, Scotland
[3] Massachusetts Gen Hosp, Dept Med, Clin & Translat Epidemiol Unit, Boston, MA 02114 USA
[4] Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA
[5] Harvard Med Sch, Boston, MA USA
关键词
INFLAMMATORY-BOWEL-DISEASE; SELECTIVE CYCLOOXYGENASE-2 INHIBITORS; CLINICAL RELAPSE; ASPIRIN; ROFECOXIB; INGESTION; SAFETY; COHORT; FLARES;
D O I
10.1111/apt.14606
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Unlike acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDs) have generally been thought to be associated with increased risk of IBD exacerbation. Aim: To carry out a systematic review and meta-analysis of previous studies examining the association between acetaminophen and NSAIDs including cyclooxygenase (COX-2) inhibitors use, and risk of Crohn's disease (CD) and ulcerative colitis (UC) exacerbation. Methods: We identified published manuscripts and abstracts through 1 March 2017 by systematic search of Medline, Embase, Cochrane and other trial registries. Quality assessment was done using Newcastle-Ottawa scale and random-effect meta-analysis using pooled relative risks (RRs) and 95% CIs were calculated. Results: Eighteen publications between years 1983 and 2016 were identified. For the meta-analysis, pooled RRs of disease exacerbation with NSAIDs use were (1.42, 95% CI, 0.65-3.09), I-2=60.3% for CD, and (1.52, 95% CI, 0.87-2.63), I-2=56.1% for UC. The corresponding values for acetaminophen use were (1.40, 95% CI, 0.96-2.04), I-2=45.6% for UC, and (1.56, 95% CI, 1.22-1.99), I-2=0.0% for IBD. Sensitivity analyses limited to studies with low risk of bias showed a significantly increased risk of CD exacerbation (1.53, 95% CI, 1.08-2.16) but not UC (0.94, 95% CI, 0.36-2.42) with NSAIDs use. Conclusions: Contrary to generally accepted belief, we did not find a consistent association between NSAIDs use and risk of CD and UC exacerbation. There was also no consistent evidence for association with acetaminophen although further studies are needed.
引用
收藏
页码:1428 / 1439
页数:12
相关论文
共 53 条
  • [1] Aspirin, Nonsteroidal Anti-inflammatory Drug Use, and Risk for Crohn Disease and Ulcerative Colitis A Cohort Study
    Ananthakrishnan, Ashwin N.
    Higuchi, Leslie M.
    Huang, Edward S.
    Khalili, Hamed
    Richter, James M.
    Fuchs, Charles S.
    Chan, Andrew T.
    [J]. ANNALS OF INTERNAL MEDICINE, 2012, 156 (05) : 350 - U170
  • [2] [Anonymous], J DIG DIS
  • [3] [Anonymous], IMPACT NONSTEROIDAL
  • [4] [Anonymous], GASTROENTEROLOGY
  • [5] [Anonymous], AM J GASTROENTERO S1
  • [6] [Anonymous], GASTROENTEROLOGY
  • [7] [Anonymous], RECOMMENDATIONS EXAM
  • [8] A suggestion for quality assessment in systematic reviews of observational studies in nutritional epidemiology
    Bae, Jong-Myon
    [J]. EPIDEMIOLOGY AND HEALTH, 2016, 38 : e2016014
  • [9] A Prospective Population-Based Study of Triggers of Symptomatic Flares in IBD
    Bernstein, Charles N.
    Singh, Sunny
    Graff, Lesley A.
    Walker, John R.
    Miller, Norine
    Cheang, Mary
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2010, 105 (09) : 1994 - 2002
  • [10] Rofecoxib and early relapse of inflammatory bowel disease: an open-label trial
    Biancone, L
    Tosti, C
    Geremia, A
    Fina, D
    Petruzziello, C
    Emerenziani, S
    Pallone, F
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2004, 19 (07) : 755 - 764